Precision (DTIL) Drops 7.38% on June 23

Equities Staff  |

Shares of Precision Biosciences Inc (NASDAQ: DTIL) moved 7.38% Thursday.

As of 11:54:10 est, Precision  sits at $1.45 and dropped $0.11 per share in trading so far.

Precision has moved 11.31% over the last 30 days and has moved YTD 79.86% based on the prior day’s close.

The company anticipates its next earnings on 2022-08-09.

For technical charts, analysis, and more on Precision visit the company profile.

About Precision Biosciences Inc

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple 'off-the-shelf' CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.

To get more information on Precision Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Precision Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content